Cargando…

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer

Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. Because chemokine network is involved in OC progression, we evaluated associations between chemokine expression and survival in tumor suppressor protein p53 (TP53) wild-type (TP53WT) and mutant (TP53m) OC datasets....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ignacio, Rosa Mistica C., Lee, Eun-Sook, Wilson, Andrew J., Beeghly-Fadiel, Alicia, Whalen, Margaret M., Son, Deok-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Immunologists 2018
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117514/ https://www.ncbi.nlm.nih.gov/pubmed/30181917 http://dx.doi.org/10.4110/in.2018.18.e29

Ejemplares similares

Obesity-Induced Peritoneal Dissemination of Ovarian Cancer and Dominant Recruitment of Macrophages in Ascites
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Potential Roles of Innate Immune Chemokine and Cytokine Network on Lipopolysaccharide-Based Therapeutic Approach in Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2019)

High-Fat Diet-Induced Obese Effects of Adipocyte-Specific CXCR2 Conditional Knockout in the Peritoneal Tumor Microenvironment of Ovarian Cancer
por: Choe, Deokyeong, et al.
Publicado: (2021)

Differential Chemokine Signature between Human Preadipocytes and Adipocytes
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2016)

The TGFα-EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
por: Davidson, Brittany Anne, et al.
Publicado: (2014)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2016)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature
por: Hufnagel, Demetra H., et al.
Publicado: (2020)

Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors
por: Choi, Hyeongjwa, et al.
Publicado: (2017)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
por: Kogan, Aksinija A., et al.
Publicado: (2022)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium
por: Archibald, Kyra M, et al.
Publicado: (2012)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Comparison of Modules of Wild Type and Mutant Huntingtin and TP53 Protein Interaction Networks: Implications in Biological Processes and Functions
por: Basu, Mahashweta, et al.
Publicado: (2013)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
por: Wang, Zhijie, et al.
Publicado: (2017)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

Blood type, ABO genetic variants, and ovarian cancer survival
por: Cozzi, Gabriella D., et al.
Publicado: (2017)

Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records
por: Cozzi, Gabriella D., et al.
Publicado: (2016)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage
por: Pardo, F S, et al.
Publicado: (2004)

Different TP53 mutants in p53 overexpressed epithelial ovarian carcinoma can be associated both with altered and unaltered glycolytic and apoptotic profiles
por: Antoun, Stephanie, et al.
Publicado: (2018)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Localization of Serum Amyloid A3 in the Mouse Ovary
por: Choi, Hyeongjwa, et al.
Publicado: (2017)

Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nlse22287up4ugt9hf7fdfrom3